Skip to main content

Table 2 Meta-analysis results using calculated unadjusted ORs

From: Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis

Analysis for unadjusted mortality data Studies (N) Calculated OR (95% CI)
Totally high-risk patient populations 8 5.85 (3.69, 9.26); I2 = 19.8%
 Low risk of bias 6 5.07 (3.38, 7.59); I2 = 0.0%
 CS infection comparator 5 5.24 (2.65, 10.37); I2 = 32.1%
 No CR infection comparator 3 7.02 (3.33, 14.80); I2 = 18.4%
 No infection comparator 2 24.76 (4.14, 148.00); I2 = 71.4%
 In-hospital/≤30-day mortality 4 6.08 (3.83, 9.66); I2 = 0.0%
 Longer-term (> 30 days) mortality 5 6.56 (2.81, 15.33); I2 = 51.3%
 Italy 3 5.86 (3.65, 9.41); I2 = 0.0%
 USA 5 5.40 (2.58, 11.30); I2 = 34.1%
Partially and totally high-risk patient populations 14 4.13 (2.70, 6.31); I2 = 71.5%
 Low risk of bias 9 3.94 (2.32, 6.68); I2 = 71.4%
 CS infection comparator 10 3.39 (2.11, 5.45); I2 = 70.2%
 No CR infection comparator 3 7.02 (3.33, 14.80); I2 = 18.4%
 No infection comparator 3 13.39 (4.09, 43.87); I2 = 75.0%
 In-hospital/≤30-day mortality 10 3.74 (2.37, 5.89); I2 = 74.2%
 Longer-term (> 30 days) mortality 5 6.56 (2.81, 15.33); I2 = 51.3%
 CRKP studies only 12 4.68 (3.03, 7.23); I2 = 61.0%
 CRPA studies only 2 2.25 (0.84, 6.03); I2 = 77.6%
 Italy 5 4.21 (2.17, 8.14); I2 = 73.3%
 USA 9 3.83 (2.54, 5.76); I2 = 28.1%
  1. CI Confidence interval, CRKP Carbapenem-resistant Klebsiella pneumoniae, CRPA Carbapenem-resistant Pseudomonas aeruginosa, CS Carbapenem-susceptible, N Number, OR Odds ratio
\